Leap Therapeutics, Inc. (LPTX) DCF Valuation

Valuación de DCF de Leap Therapeutics, Inc. (LPTX)

US | Healthcare | Biotechnology | NASDAQ
Leap Therapeutics, Inc. (LPTX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Leap Therapeutics, Inc. (LPTX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¿Busca evaluar el valor intrínseco de Leap Therapeutics, Inc.? Nuestra calculadora DCF (LPTX) integra datos del mundo real con características integrales de personalización, lo que le permite refinar sus pronósticos y tomar decisiones de inversión más informadas.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 1.5 1.5 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 -100 0 -25 -25 -25 -25 -25
EBITDA -32.1 -26.8 -40.0 -54.0 -81.0 .0 .0 .0 .0 .0
EBITDA, % 100 -1787.27 -2667.6 100 100 20 20 20 20 20
Depreciation .8 .7 .6 .4 .4 .0 .0 .0 .0 .0
Depreciation, % 100 44.53 37.07 100 100 76.32 76.32 76.32 76.32 76.32
EBIT -32.9 -27.5 -40.6 -54.4 -81.4 .0 .0 .0 .0 .0
EBIT, % 100 -1831.8 -2704.67 100 100 20 20 20 20 20
Total Cash 3.9 52.1 114.9 65.5 70.6 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .2 .1 1.2 2.1 .8
Account Receivables, % 100 4.87 79.27 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 0 0 100 100 60 60 60 60 60
Accounts Payable 4.6 2.7 4.2 5.7 6.5 .0 .0 .0 .0 .0
Accounts Payable, % 100 181.13 279.27 100 100 100 100 100 100 100
Capital Expenditure -.1 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 0 0 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -32.9 -27.5 -40.5 -54.5 -81.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -27.8 -28.5 -39.6 -53.6 -78.9 -5.7 .0 .0 .0 .0
WACC, % 5.47 5.47 5.47 5.47 5.47 5.47 5.47 5.47 5.47 5.47
PV UFCF
SUM PV UFCF -5.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -5
Net Debt -70
Equity Value 65
Diluted Shares Outstanding, MM 20
Equity Value Per Share 3.18

What You Will Receive

  • Comprehensive Financial Model: Leap Therapeutics’ actual data supports accurate DCF valuation.
  • Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
  • Real-Time Calculations: Automatic updates allow you to see outcomes as you adjust inputs.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Adaptable and Reusable: Designed for versatility, enabling repeated use for in-depth forecasts.

Key Features

  • Customizable Clinical Parameters: Adjust vital inputs such as patient demographics, treatment efficacy, and trial durations.
  • Automated Valuation Models: Instantly computes intrinsic value, NPV, and other key metrics.
  • High-Precision Analytics: Leverages Leap Therapeutics' actual financial data for credible valuation results.
  • Streamlined Scenario Testing: Easily evaluate various assumptions and analyze outcomes side by side.
  • Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file for Leap Therapeutics, Inc. (LPTX).
  2. Step 2: Review the pre-filled financial data and forecasts specific to Leap Therapeutics.
  3. Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you modify your assumptions.
  5. Step 5: Evaluate the outputs and leverage the results for your investment strategies.

Why Choose Leap Therapeutics Calculator?

  • Accuracy: Utilizes real Leap Therapeutics financials to ensure precise data.
  • Flexibility: Crafted for users to easily test and adjust inputs as needed.
  • Time-Saving: Eliminate the need to create a DCF model from the ground up.
  • Professional-Grade: Designed with CFO-level precision and user experience in mind.
  • User-Friendly: Simple to navigate, even for those without extensive financial modeling background.

Who Should Use This Product?

  • Investors: Assess Leap Therapeutics’ valuation before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
  • Startup Founders: Understand the valuation strategies of established biotech companies like Leap Therapeutics.
  • Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
  • Students and Educators: Utilize real-time data to learn and teach valuation principles in biotechnology.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Leap Therapeutics, Inc. (LPTX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Leap Therapeutics, Inc. (LPTX).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.